Nabriva Therapeutics, a Vienna, Austria-baseed biotechnology company focused on developing a new class of antibiotics for serious infections caused by resistant pathogens, announced the closing of a €15M financing from existing investors including Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures, and Novartis Venture Fund.
This round brings the total equity funding raised by the company to €57.4m (approximately $84m) since its foundation in 2006.
Commenting on the financing, Dr. David Chiswell, CEO of Nabriva Therapeutics, said: “These additional funds extend Nabriva’s cash reach into 2011 and will fund the development of our systemic pleuromutilin program up to and including the generation of phase II efficacy data in the second half of 2010”.
FinSMEs
28/10/2009